Valye reports for unlimited access

UniFirst Corporation, established in 1950, provides workplace uniforms and protective clothing services across North America and Europe. Its operations include designing, manufacturing, renting, cleaning, and selling uniforms and related products, serving over 300,000 customer locations. The company operates through three segments: Uniform & Facility Service Solutions, First Aid & Safety Solutions, and Other, which includes nuclear-related services. UniFirst is undertaking a multiyear ERP project to enhance operational efficiency and supply chain management. The company faces risks from inflation, tariffs, and geopolitical factors that may affect costs and customer demand. In March 2026, UniFirst entered a merger agreement with Cintas, involving a cash and stock transaction for shareholders.

Londax Corp. is a Wyoming-incorporated developmental-stage company specializing in IT consulting and software development. Its main product, londax.ai, is a cloud-hosted CRM system with integrated Applicant Tracking and out-staffing services, designed to help clients manage recruitment and personnel efficiently. The system leverages AI technology via the OpenAI API for advertisement generation and offers a range of features including recruitment funnels, job posting creation, and employee profile management. The company targets small to midsize businesses in Europe with plans for broader geographic reach. Revenue is generated through subscription fees, customization, data migration, training, integration, maintenance, and upgrades. Marketing efforts focus on online channels and social media engagement. The company currently has only one part-time employee, its president, and is subject to various EU regulations including GDPR and consumer protection laws.

UniFirst Corporation, established in 1950 and headquartered in Massachusetts, is a leading provider of workplace uniforms and protective clothing in North America. The company designs, manufactures, rents, cleans, delivers, and sells a broad range of uniforms and protective garments, including specialized items such as flame resistant and high visibility apparel. UniFirst also offers industrial wiping products, floor mats, facility service products, restroom and cleaning supplies, first aid cabinet services, safety supplies, and safety training. Serving over 300,000 customer locations across the U.S., Canada, and Europe, UniFirst operates through three reportable segments: Uniform & Facility Service Solutions, First Aid & Safety Solutions, and Other, which includes its nuclear business. The company is undertaking a significant ERP system upgrade to improve operational efficiency and customer retention. In March 2026, UniFirst entered into a merger agreement with Cintas, a major competitor in the uniform services industry.

APEX Tech Acquisition Inc. is a Cayman Islands exempted company that completed its initial public offering in February 2026 as a special purpose acquisition company (SPAC). The IPO raised approximately $112 million through the sale of units consisting of ordinary shares and rights to additional shares upon a business combination. The company currently holds these proceeds in a trust account pending an initial business combination. As of the latest SEC filing period ending February 28, 2026, the company has no reported revenue and has recorded a net loss of $39,322 USD. The company is listed on the New York Stock Exchange under the ticker TRAD for ordinary shares and TRADR for rights.

Jaguar Health, Inc. operates in the pharmaceutical sector focusing on gastrointestinal health products for humans and animals. Its lead human health product, Mytesi, is FDA-approved for treating noninfectious diarrhea in adults with HIV/AIDS. The company also markets Canalevia-CA1 for chronic inflammatory diarrhea in dogs. Jaguar Health acquired Napo Pharmaceuticals in 2017, which is integral to its operations. The company has a licensing agreement with Woodward Specialty LLC granting exclusive commercialization rights for Mytesi and Canalevia in the U.S. Jaguar Health is developing additional products including Gelclair for oral mucositis and NP-300. The company has a limited operating history, with revenues insufficient to offset expenses, and has reported significant net losses. It relies on two suppliers for the key raw material crofelemer and third-party manufacturers for production. Jaguar Health faces competition from established pharmaceutical companies in the gastrointestinal space and is subject to regulatory and financial risks.

CPI Aerostructures, Inc. (CPI Aero) operates in the aerospace and defense sector, manufacturing structural assemblies, integrated systems, and providing kitting and MRO services. The company serves both domestic and international markets, primarily as a prime contractor to the U.S. Department of Defense and as a Tier 1 subcontractor to major aerospace and defense contractors. CPI Aero's product portfolio includes aerostructures such as wing structures and engine inlets, aerosystems including airborne pod structures, tube bending, specialty welding, and electrical harnesses. The company emphasizes build-to-print manufacturing and engineering services, supporting customer programs with program management, supply chain management, and quality assurance. CPI Aero competes with larger Tier 1 suppliers and internal manufacturing arms of customers, focusing on smaller modification awards and government small business set-aside contracts. The company has a history dating back to 1980 and has expanded capabilities through acquisitions and contract awards. Its customer base includes Lockheed Martin, RTX Corporation, Northrop Grumman, and commercial aerospace OEMs. CPI Aero operates as a single segment and manages its business on a consolidated basis [S1][S2].

Cell Source, Inc. focuses on developing cell therapy products that modulate the immune system to enable safer and more effective allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapies. The company’s proprietary Veto Cell technology, licensed from the Weizmann Institute, is designed to induce sustained immune tolerance to transplanted cells or organs, reducing the need for aggressive immune suppression and associated risks such as graft versus host disease (GvHD) and infections. Clinical development is centered at MD Anderson Cancer Center, with ongoing Phase 1/2 trials evaluating safety and efficacy in blood cancer patients. The company targets hematological malignancies initially, with plans to expand into organ transplantation and non-malignant hematological disorders. Cell Source operates production centers in key geographic regions and plans a staged market entry focusing on leading transplantation centers. The company holds exclusive worldwide licenses to relevant patents and intellectual property. Financially, Cell Source is an early-stage company with no revenues to date, reporting net losses and liquidity constraints as of the latest filings.

Cambium Networks Corp, through its subsidiary Cambium Networks, Ltd., develops and sells wireless broadband solutions including fixed wireless broadband, Wi-Fi, and enterprise network edge products. The company relies on third-party manufacturers predominantly outside the U.S. and sells primarily through a concentrated base of distributors and channel partners. It has a global presence with operations in 25 countries and a workforce of approximately 486 employees as of late 2025. The company has experienced significant financial and operational challenges, including delisting from Nasdaq in March 2026 due to noncompliance with listing rules, material weaknesses in internal controls, and substantial doubt about its ability to continue as a going concern due to credit covenant defaults. Cambium Networks operates in a highly competitive and rapidly evolving wireless broadband market with competitors such as Ericsson, Nokia, Ubiquiti, and Cisco Meraki. The company faces risks related to supply chain disruptions, international trade regulations, and fluctuating demand.

Titan Acquisition Corp. is a special purpose acquisition company incorporated in the Cayman Islands. It completed its initial public offering in early 2025, issuing units consisting of Class A ordinary shares and warrants. The company’s securities are listed on The Nasdaq Stock Market. As a SPAC, its primary business model involves raising capital through the IPO and holding funds in a trust account until a business combination is identified and completed. As of December 31, 2025, the company held approximately $285.6 million in trust account investments and had cash and cash equivalents of $720,301. The company reported net income of $7.2 million for the fiscal year ended December 31, 2025. Liquidity ratios indicate a current ratio of 1.19 and a cash ratio of 1.03 at year-end 2025. The company disclosed substantial doubt about its ability to continue as a going concern without raising additional funds. Trading of Class A shares and warrants separately from IPO units commenced in May 2025.

Tsakos Energy Navigation Ltd (TEN) is a Bermuda-incorporated shipping company engaged in vessel operations and related shipping income. The company operates under Bermuda and Greek law, with no current capital or dividend remittance restrictions for nonresident shareholders. TEN's shares are primarily traded on the New York Stock Exchange, satisfying U.S. tax exemption criteria for its shipping income. The company reported nearly $799 million in revenue and $161 million in net income for fiscal year 2025, with a solid cash position and liquidity ratios close to parity. Management changes in early 2026 include the appointment of a new Chief Financial Officer. TEN receives regular analyst coverage and media attention, including features in TIME Magazine Europe and dividend announcements.

Dave & Buster's Entertainment, Inc. is a Delaware corporation headquartered in Coppell, Texas, operating a network of 243 stores as of early 2026. The company offers combined entertainment and dining experiences targeting adults and families, with two main brands: Dave & Buster's and Main Event. The business is managed as a single operating segment with similar products and customer demographics. Revenue streams include entertainment (redemption and simulation games, bowling, laser tag, billiards, gravity ropes) and food and beverage sales (full meals, appetizers, alcoholic and non-alcoholic drinks). The company recognizes entertainment revenue based on game play credit usage and defers revenue related to unused credits and ticket redemptions. Food and beverage revenues are recognized at point of sale, including delivery services fulfilled by third parties. The company monitors comparable store sales and new store openings as key performance indicators. Fiscal 2025 saw a modest decline in total revenues and comparable store sales, with increased operating costs and a net loss reported. Liquidity is maintained through cash reserves and credit facilities, with ongoing capital expenditures for new stores, remodels, and game investments.

Alaunos Therapeutics, Inc. is a preclinical-stage biopharmaceutical company focused on developing novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders such as MASLD. The company’s lead program, ALN1003, employs a differentiated non-hormonal, non-incretin mechanism distinct from hormone-based therapies like GLP-1 receptor agonists. Positive preclinical data from two diet-induced obesity mouse model studies demonstrated dose-dependent body weight loss, favorable body composition changes, reductions in liver weight, and improvements in liver function and metabolic biomarkers. The company previously focused on clinical-stage oncology cell therapy programs but discontinued these in August 2023 due to high costs and financing challenges. Alaunos has not generated product revenue and has incurred significant net losses since inception. It outsources manufacturing to third-party CDMOs and is engaged in chemistry, manufacturing, and controls activities to optimize formulations and scale production. Intellectual property protection efforts include pending patent applications and computational chemistry programs to develop analogs. The company faces risks related to capital needs, regulatory approval, competition, and Nasdaq listing compliance.

American Clean Resources Group, Inc. (ACRG) is an exploration stage company with administrative offices in Lakewood, Colorado, and owns property in Tonopah, Nevada. The company plans to construct a permitted custom processing toll milling facility on its Tonopah property, which will include an analytical laboratory, a pyrometallurgical plant, and a hydrometallurgical recovery plant. The toll milling process involves crushing and grinding mined material to facilitate extraction of precious metals such as gold, silver, and platinum group metals. The company also intends to offer chemical production outsourcing services for industrial clients lacking in-house expertise or permits. ACRG has not yet commenced revenue-generating operations and must obtain several permits before construction and operation can begin. The company owns significant land assets, including approximately 1,186 deeded acres with an estimated 2.2 million tons of historic tailings. The business plan and operations remain subject to significant uncertainties, including permit acquisition and financing.

Karman Holdings Inc. is a company engaged in the defense and aerospace sector, with recent expansion through acquisition of Seemann Composites and Materials Sciences. The company finances its operations through credit agreements that have been amended to increase borrowing capacity and reduce interest rates. Financial disclosures indicate positive net income and a solid liquidity position as of the end of 2025. Public news coverage focuses on the company's stock performance, analyst recommendations, and ETF inflows, reflecting market interest and activity.

Generation Income Properties, Inc. is a real estate company listed on Nasdaq under the ticker GIPR. The company owns and manages commercial real estate assets, including office and retail properties. In 2025, it completed sales of properties in Maitland, Florida and Grand Junction, Colorado, using proceeds to reduce mortgage debt. The company reported revenue of approximately $9.74 million and a net loss of $10.34 million for the fiscal year ended December 31, 2025. Cash and cash equivalents stood at about $6.16 million at year-end. The company is engaged in managing its Nasdaq listing compliance and has recently undergone leadership changes and strategic reviews.

AZUL SA operates as a major Brazilian airline with a broad domestic and international route network. The company focuses on providing frequent, affordable air service using a modern fleet, supplemented by ancillary businesses such as loyalty programs, cargo, and travel packages. The airline has undergone significant restructuring, including a Chapter 11 reorganization completed in late 2025, which reshaped its capital structure and fleet profile. AZUL's business model emphasizes network connectivity within Brazil and select international destinations, leveraging partnerships such as with United Airlines. The company manages operational costs through productivity improvements and fleet modernization, while navigating macroeconomic challenges and legal claims.

MDxHealth SA is a commercial-stage precision diagnostics company incorporated in Belgium in 2003. It focuses on non-invasive, clinically actionable, and cost-effective molecular diagnostic solutions for urologic diseases, primarily prostate cancer and urinary tract infections. The company’s core product portfolio includes Confirm mdx, GPS mdx, and Exo mdx tests, which provide personalized genomic insights to guide prostate cancer screening, diagnosis, and treatment decisions. The Exo mdx test, acquired in 2025, is a non-invasive urine test with a 91% negative predictive value for clinically significant prostate cancer, helping to reduce unnecessary biopsies. Confirm mdx and GPS mdx tests further aid in biopsy accuracy and risk stratification for treatment planning. The company also offers Resolve mdx, a rapid urinary tract infection test delivering patient-specific antibiotic recommendations. MDxHealth’s tests are recognized in major clinical guidelines such as NCCN and reimbursed by Medicare and commercial payors. The company operates CAP accredited and CLIA certified laboratories and maintains a direct sales force in the United States, targeting urology-focused networks. It continues to develop new tests, including Monitor mdx for active surveillance of prostate cancer. MDxHealth’s shares trade on Nasdaq under the ticker MDXH following delisting from Euronext Brussels in 2023.

Banzai International, Inc. operates as a Software as a Service (SaaS) company in the marketing technology (MarTech) sector, offering a comprehensive platform of AI-powered marketing tools designed to improve efficiency and impact for its customers. The company supports over 150,000 customers worldwide, including major enterprises such as Amazon and Salesforce. Its product suite includes solutions for video creation (OpenReel, CreateStudio), video hosting and marketing (Vidello), webinar hosting (Demio), webinar attendance boosting (Boost), targeted outreach (Reach), and AI-driven newsletters (Curate). Banzai's business model primarily relies on recurring subscription licenses with contract terms ranging from monthly to multi-year. The company pursues growth through organic customer acquisition, product development, cross-selling, and strategic acquisitions, including recent purchases of OpenReel, Vidello, and Superblocks. Banzai employs a hybrid go-to-market approach combining self-service and direct sales channels. The company is publicly traded on the Nasdaq Capital Market under the ticker BNZI.

TurnOnGreen, Inc. is a technology company specializing in premium custom power products and electric vehicle (EV) electrification infrastructure solutions. It operates through two wholly owned subsidiaries: Digital Power Corporation (DPC), which focuses on designing and manufacturing high-grade power conversion and power system solutions for diverse sectors such as e-Mobility, medical, military, telecommunications, and industrial markets; and TOG Technologies Inc. (TOGT), which markets scalable EV charging products and comprehensive charging management software and network services. The company leverages proprietary core power technologies, including integrated circuit implementations, to deliver cost-effective, high-efficiency, and high-density power solutions tailored to customer needs. TurnOnGreen aims to be the supplier of choice in markets requiring custom design, superior product quality, rapid time to market, and competitive pricing. The company serves mission-critical applications and has diversified its customer base across commercial, defense, and public sectors.

REGO Payment Architectures, Inc. is a Delaware-based FinTech company offering the Mazoola® digital wallet platform, targeting families with minors under 13 years old. The platform enables secure, compliant mobile payments and financial education under parental oversight. REGO's business model focuses on white label licensing, partnerships with financial institutions, and revenue sharing. The company emphasizes compliance with privacy laws such as COPPA, GDPR, and state-level regulations, and holds four US patents. It aims to serve the growing digital-native Gen Z and Gen Alpha demographics, as well as aging parents needing financial management tools. REGO faces a competitive payments industry landscape but differentiates through its family-centric, privacy-compliant approach. As of the end of 2025, the company had limited revenue and significant net losses, with a small employee base and outsourced development and marketing functions [S1][N1].

Skinvisible, Inc. operates through its subsidiary Skinvisible Pharmaceuticals Inc. as a pharmaceutical research and development company focused on its patented polymer delivery system, Invisicare®. This technology enhances topical delivery of active ingredients by extending their duration on the skin and improving efficacy while reducing irritation. The company has developed over forty topical skin products using Invisicare and targets large global markets in skincare, dermatology, over-the-counter products, and is exploring applications in obesity and other medical areas. Skinvisible's business model centers on out-licensing its patented products to established manufacturers and marketers worldwide, generating revenue from upfront fees and royalties. The company also provides co-development services and life cycle management by reformulating products coming off patent. Key license agreements include one with Quoin Pharmaceuticals for the development and commercialization of QRX003, a product in late-stage clinical trials for Netherton Syndrome, and another with Ovation Science for hand sanitizer and cannabinoid-based topical products targeting obesity and metabolic health. Skinvisible has filed provisional patents for transdermal delivery compositions for obesity drugs and glucose-controlling agents. Financially, the company reported minimal revenue and a net loss for the year ended December 31, 2025, with liquidity challenges and an accumulated deficit. The company is dependent on licensing revenue, regulatory approvals, and raising additional capital to continue operations.

Israel Acquisitions Corp is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in 2021. The company’s purpose is to complete a business combination with one or more target businesses. As of the end of 2025, the company had not commenced operations or completed a business combination. The company’s financial position includes cash and marketable securities held in a trust account, related party promissory notes, and accrued expenses. The company’s securities were delisted from Nasdaq in December 2025 due to failure to maintain minimum market value and now trade on the Pink Limited Market. The company is classified as an emerging growth company and faces typical risks associated with blank check companies, including uncertainty about completing a business combination and obtaining additional financing.

374Water Inc. develops AirSCWO technology designed to treat hazardous wastes, including PFAS-contaminated materials, through supercritical water oxidation processes. The company is in the early stages of commercializing this technology, having sold one system to date. Its business model relies heavily on government contracts and partnerships to deploy its technology in environmental remediation projects. The company faces challenges typical of early-stage technology firms, including limited operating history, ongoing net losses, and the need to scale production and sales. Management turnover and identified material weaknesses in financial controls add complexity to execution. The company has demonstrated its technology's effectiveness in Department of Defense projects and has formed strategic partnerships to advance deployment. Liquidity metrics as of the end of 2025 show the company maintains sufficient current assets relative to liabilities but continues to operate at a loss.

Cal Redwood Acquisition Corp. is a Cayman Islands exempted blank check company incorporated in January 2025. Its business purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more target businesses. The company intends to focus on technology, media, and telecommunications (TMT) sectors and industries undergoing technology disruption. It completed its initial public offering in May 2025, raising gross proceeds of $230 million plus $6.6 million from a private placement, with proceeds held in a trust account invested primarily in U.S. Treasury Bills. The company has not generated operating revenues and does not expect to do so until after consummation of its initial business combination. It announced a definitive business combination agreement with Carvix, Inc. in March 2026, with Thunder Rock Capital serving as exclusive financial advisor.

NEXGEL, INC. is a Delaware-incorporated company specializing in the manufacture of high water content, electron beam cross-linked aqueous polymer hydrogels used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company operates primarily as a contract manufacturer supplying gels to third parties, while also marketing its own branded consumer products and offering custom and white label hydrogel products. Its manufacturing facility in Pennsylvania operates at 15-20% capacity with significant room for expansion. The company is also developing medical devices such as NEXDrape and NEXDerm, focusing on licensing and partnerships for commercialization. NEXGEL faces competition from large established healthcare and consumer product companies and relies on a limited number of raw material suppliers. Sales are made on a purchase order basis without long-term contracts, leading to potential variability in revenue. The company reported a net loss in 2025 and has material weaknesses in financial controls. Recent strategic moves include a licensing and acquisition agreement with Celularity and leadership changes [S1][N3][N1].

Cartesian Growth Corp II is a Special Purpose Acquisition Company (SPAC) incorporated in the Cayman Islands in October 2021. Its purpose is to complete a business combination with one or more target companies, focusing on high-growth businesses with transnational operations. The company raised gross proceeds of $230 million in its May 2022 IPO, with additional funds from private placement warrants and sponsor loans. The company has not yet completed a business combination and has not generated operating revenues. Its securities were delisted from Nasdaq in May 2025 due to failure to complete a business combination within the required timeframe and now trade on the OTC Pink market. The company has extended the deadline to complete a business combination multiple times, with the current deadline set for August 5, 2026. It holds funds in a trust account to be used for the business combination or shareholder redemptions if no combination occurs. The company incurs operating costs related to public company compliance and due diligence activities. Liquidity constraints and the approaching deadline raise substantial doubt about the company's ability to continue as a going concern.

Streamex Corp. is a technology company that expanded its business in 2025 through the acquisition of Streamex Exchange Corporation, shifting from a medical device focus to a diversified platform centered on tokenized finance and real-world asset digitization. The company operates a blockchain-based infrastructure enabling issuance and trading of digital tokens backed by physical commodities, starting with gold. The legacy PURE EP™ Platform for cardiac electrophysiology remains part of the business but with limited recent commercial activity. As of the end of 2025, the tokenization platform was in development with no significant revenue, and the company reported substantial net losses primarily due to non-cash accounting charges and increased stock-based compensation. Streamex has strengthened its liquidity through public offerings and asset sales and manages its operations as a single reportable segment. The company also holds majority interests in subsidiaries with dormant or paused operations, evaluating strategic alternatives for these entities.

Aptose Biosciences Inc. is a science-driven clinical-stage biotechnology company developing precision medicines targeting unmet needs in oncology, with an initial focus on hematologic malignancies such as AML and hr-MDS. The company’s lead clinical candidate, tuspetinib, is an oral kinase inhibitor designed to target key kinases involved in tumor proliferation and resistance mechanisms while avoiding toxicities common to other kinase inhibitors. Tuspetinib is being developed primarily as a frontline combination therapy with venetoclax and azacitidine, investigated in the Phase 1/2 TUSCANY trial. Clinical data have shown promising safety and efficacy, including high complete remission rates and minimal residual disease negativity across diverse mutational subtypes. Aptose has a licensing agreement with Hanmi Pharmaceutical granting exclusive worldwide rights to tuspetinib and has entered into a definitive arrangement agreement for acquisition by Hanmi, with shareholder approval obtained in March 2026. The company’s financial position as of December 31, 2025, reflects ongoing operating losses and liquidity challenges, with reliance on financing from Hanmi and equity issuances to support clinical development and operations.

New Concept Energy, Inc. is a Nevada-based company with a history dating back to 1982 through predecessor entities. Its current operations focus on real estate leasing and advisory services for oil and gas operations. The company owns approximately 190 acres in Parkersburg, West Virginia, with four structures totaling about 53,000 square feet. The main industrial/office building has about 16,000 square feet leased, generating rental income. In 2020, the company sold its oil and gas wells and mineral leases but continues to provide management and advisory services under a consulting agreement that entitles it to 10% of the revenue from these wells. The company employs two people directly and outsources other work. It maintains property and liability insurance and has no long-term debt. Financially, the company reported $155,000 in revenue and a net loss of $46,000 for the year ended December 31, 2025, with strong liquidity ratios. The company’s stock trades on the NYSE American under the ticker GBR, with no dividends paid in recent years.

Netskope Inc is a technology company specializing in cybersecurity solutions. The company went public in September 2025, restructuring its share classes as part of the IPO. It generates revenue primarily through its cybersecurity products and services, though detailed product segmentation is not disclosed. Netskope maintains a strong liquidity position with over $1.1 billion in combined cash, cash equivalents, and short-term investments as of January 31, 2026. The company reports losses at the net income level, reflecting ongoing investments in growth and operations.

Liminatus Pharma, Inc. is a Nasdaq-listed emerging growth company with limited publicly disclosed information about its core business operations or industry classification. The company reported significant net losses and liquidity constraints as of the end of 2025. It has been subject to Nasdaq notifications for non-compliance with listing standards related to market value and bid price, with ongoing efforts to regain compliance. Recent corporate activities include capital raising through a public offering of shares and warrants and a strategic review of treasury management involving regulated digital assets.

New Providence Acquisition Corp. III is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in December 2024. Its business model is to raise capital through an IPO and then identify and complete a business combination with a target company, potentially in any industry. The company completed its IPO in April 2025, issuing over 30 million units and raising over $300 million, which are held in a trust account. It has no operating revenues to date and does not expect to generate revenues until after completing its initial business combination. The company is currently pursuing a business combination with Abra, including a merger agreement signed in March 2026. The management team has prior SPAC experience and a network to source acquisition targets. The company must complete its business combination by April 2027 or liquidate and return funds to shareholders. It may seek additional financing to complete the combination, which could affect shareholder dilution and capital structure.

Reliability Inc, headquartered in Maryland, operates primarily through its wholly owned subsidiary, The Maslow Media Group, Inc., offering workforce solutions including Employer of Record (EOR) services, staffing solutions, managed services, and video production services. The company serves a diverse client base across media, financial services, healthcare, telecommunications, pharmaceuticals, energy, and education sectors, both domestically and internationally. Maslow has expanded from media production management into broader workforce management, including IT, creative, marketing, and administrative staffing. The company’s EOR services manage employee lifecycle and compliance risks, while staffing solutions cover temporary, contract, direct hire, and managed services. Video production services encompass pre-production through live broadcast and studio management. The company’s revenue declined in 2025 due to reduced activity from major clients and client attrition, with a net loss reported. Liquidity is supported by cash, receivables financing, and factoring arrangements. The company resolved a significant arbitration dispute with the Vivos Group in 2026, leading to share transfers to the company. The staffing industry is cyclical and influenced by macroeconomic and regulatory factors, with growing demand for flexible workforce models and outsourced compliance solutions.

Faraday Future Intelligent Electric Inc. operates in the electric vehicle and robotics sectors, developing advanced EAI (Electric Autonomous Intelligence) vehicles and robotics products. The company has recently launched multiple robot products across three categories and is actively engaging partners through recruitment events. It has completed U.S. regulatory certification for its first EAI Robotics product, which is poised to begin sales. Faraday Future is expanding its presence internationally, showcasing its technology in markets such as the Middle East. The company is navigating financial challenges, including significant net losses and liquidity constraints, and is currently under Nasdaq's minimum bid price compliance requirements.

Independence Power Holdings, Inc. is engaged in the deployment and operational management of a fleet of 101 modified containerized Battery Energy Storage System (BESS) units acquired from GridCore. The company operates through wholly owned subsidiaries including DBD Express and Kyma Batteries, providing asset management services for the BESS fleet under commercial agreements. It utilizes an embedded operating system and software platform to manage operations at centralized battery rental yards and field sites. The company also maintains administrative services agreements with related parties to support staffing, payroll, accounting, and other administrative functions. Additionally, it leases property in Wisconsin for warehouse, research and development, and office use. The company reported fiscal year 2025 revenue of approximately $97.2 million and maintains a strong liquidity position with a current ratio of 17.38 as of December 31, 2025. TriUnity Business Services Limited, a Nevada corporation and subsidiary, provides business administration services such as accounting, human resources management, payroll, and head-hunting primarily in Malaysia, with reported revenues of $333 and a net loss of $10,206 for the three months ended October 31, 2025.

Digi Power X Inc. develops and operates data center facilities and provides enterprise colocation and AI/GPU infrastructure services, integrating energy production with digital currency mining. The company owns a 60 MW gas-fired power plant operating as a peaker plant and participates in mining pools to generate digital currency revenues. It emphasizes sustainable energy use, sourcing 89% of its electricity from zero-carbon generation and targeting full carbon neutrality by 2026. The company holds digital assets in a Gemini account and manages mining operations with remote and on-site monitoring. As of the latest report, Digi Power X employs 17 people and reported $34.2 million in revenue with a net loss of $28.4 million for the year ended December 31, 2025.